Predictive Value of Topoisomerase IIa and Other Factors in Breast Cancer Chemotherapy
Author Information
Author(s): TAH Jarvinen, K Holi, T Kuukasjarvi, JJ Isola
Primary Institution: Tampere University Hospital
Hypothesis
Can topoisomerase IIa expression and other biomarkers predict the response to epirubicin chemotherapy in advanced breast cancer?
Conclusion
Topoisomerase IIa expression does not predict response to epirubicin chemotherapy, while c-erbB2 overexpression and negative estrogen receptor status are associated with poor response.
Supporting Evidence
- Topoisomerase IIa expression did not correlate with treatment response.
- c-erbB2 overexpression was significantly associated with poor response to chemotherapy.
- Negative estrogen receptor status predicted lower response rates.
Takeaway
Doctors wanted to see if a certain protein could help predict how well breast cancer patients would respond to a specific treatment, but it turns out it doesn't help at all.
Methodology
The study analyzed the expression of topoisomerase IIa and other biomarkers in tumor samples from 55 patients treated with epirubicin, assessing their response to treatment.
Limitations
The study only included patients treated with a single-agent chemotherapy and did not account for other potential confounding factors.
Participant Demographics
Patients with advanced breast cancer, including node-negative and node-positive cases.
Statistical Information
P-Value
0.0021
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website